ADA guidelines now include CGM use for non-insulin use, says BofA

The American Diabetes Association has released its annual guidelines and they now include continuous glucose monitor use for non-insulin use, BofA analyst Travis Steed tells investors in a research note. Bofa says this is much faster than the firm expected, and thinks this is the first step for building insurance coverage for the non-insulin products like Stelo and Lingo/Rio. The firm maintained a Buy rating and $90 price target on DexCom (DXCM) shares.